Dogs with chemotherapy-naïve MCTs presenting to the Oncology Service of a single institution were prospectively enrolled to receive escalating vinblastine, and haematology and a standardised quality-of-life questionnaire were assessed prior to each dosage.
Thirty-four dogs were included: 30 with microscopic disease treated with adequate local therapy and four with macroscopic disease.
Of 220 doses of vinblastine administered, 4% were associated with grade 3 and 4 toxicity.
A total of 70% of dogs tolerated 3.00 mg/m2 given 7 days apart at day 14 and 21, although 29% of dogs developed dose-limiting toxicities and 8% discontinued the protocol due to toxicity.
In conclusion, VPP was well-tolerated overall, although prior to further dose intensity optimisation, it is important to determine if dose intensity is linked to outcome in canine MCT to avoid unwarranted toxicity.
Source: Serra Varela, J. C., Pecceu, E., Handel, I. and Lawrence, J. (2016), Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours. Veterinary Medicine and Scienc. doi: 10.1002/vms3.42
|
